NuriFlex Holdings Inc. and Talken GmbH Sign MoU for Metaverse and NFT Wallet and Platform Project
6.1.2022 20:00:00 EET | Business Wire | Press release
NuriFlex Holdings Inc. (“NuriFlex Holdings”) announced that it has signed a memorandum of understanding (“MoU”) with Talken GmbH (“Talken”). The two companies intend to collaborate in the metaverse token project and the multichain decentralized NFT wallet and its platform (“Project”) in various regions based on robust technology and business development capabilities of the parties.
One of NuriFlex Holdings’ businesses involves the design and development of a blockchain-based metaverse ecosystem to offer various virtual worlds and related digital experiences for various services. NuriFlex Holdings is currently investing in the metaverse project that is expected to launch this year, offering global users participation in its virtual metaverse world where they can create and interact with other users like in real life.
Talken GmbH provides a service called ‘Talken’, which is a multi-chain decentralized NFT wallet supported by one of the largest Korean communities. It is a seamlessly interoperable multi-chain NFT Suite, where K-pop stars, artists, and influencers can mint, auction, store, and trade NFTs. Talken NFT Suite offers various products for every NFT lifecycle stage such as NFT wallet, NFT marketplace, simple NFT minting tool and more.
“We are excited to partner and collaborate with Talken GmbH on our metaverse and NFT platform projects. The blockchain technology experience and business development capabilities that NuriFlex Holdings and Talken GmbH bring together will be a great advantage to successfully accomplish new business opportunities and the initial step to our future token projects,” said Songman Cho, Chairman of NuriFlex Holdings Inc.
“We hope this will be the first of many partnerships to come between Nuri Group and Talken. I trust there will be many synergies to be made between Nuri’s solution for blockchain-based digital services and Talken’s unique multichain NFT platform,” said Minsu Ju, Chief Executive Officer of Talken GmbH.
About NuriFlex Holdings Inc.
Located in Vancouver, BC, Canada, NuriFlex Holdings Inc. is a parent company to the Nuri Group of companies, including NuriFlex Inc. in the USA and NuriFlex Co., Ltd. in South Korea. The NuriFlex Group of companies utilize telecommunication technologies and applications to supply a simple, convergent solution for the utilities industry, payment solution and blockchain-based digital service platform. We provide a complete energy IoT solution which enhances the utility of connected micro and smart grids throughout our clients’ systems. The blockchain embedded solution and service will be NuriFlex Group’s next-generation business. Our existing solutions will be integrated with our blockchain technology to make us one of the top integrated solution providers in the international market. Learn more at www.nuri.ca
About Talken GmbH
Talken is the multi-chain decentralized NFT wallet with the largest community. It is a seamlessly interoperable multi-chain NFT Suite, where K-pop stars, artists, and influencers can mint, auction, store, and trade NFTs. Talken is an open NFT ecosystem bridging untapped NFT enthusiasts in Korea to Talken’s native NFTs and other famous NFTs by protocols such as NBA TopShot, Rarible, OpenSea, and more. Our mission is to push for an inclusive and border-less NFT expansion and empower digital creators and collectors with better tools and services to bring NFT mainstream. Learn more at www.talken.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220107005002/en/
Contact information
NuriFlex Holdings Inc.
Elizabeth Park, CEO
ir@nuri.ca
www.nuri.ca
Talken GmbH
Minsu Ju, CEO
biz@talken.io
www.talken.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom